TD Cowen Maintains Buy on TransMedics Gr, Raises Price Target to $130
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joshua Jennings maintains a Buy rating on TransMedics Group (TMDX) and raises the price target from $100 to $130.
May 01, 2024 | 6:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TD Cowen has reaffirmed its Buy rating on TransMedics Group and increased the price target from $100 to $130.
The increase in price target by a reputable analyst like Joshua Jennings from TD Cowen suggests a strong confidence in TransMedics Group's future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term increase in TMDX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100